| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1085046161 |
| P356 | DOI | 10.1007/S11060-017-2446-4 |
| P8608 | Fatcat ID | release_x6tkemy4qbb4po7lcf3vk3vdj4 |
| P932 | PMC publication ID | 5532060 |
| P698 | PubMed publication ID | 28434112 |
| P50 | author | Mahua Dey | Q88253312 |
| P2093 | author name string | Anna C Filley | |
| P2860 | cites work | The role of IDO in brain tumor immunotherapy | Q26830399 |
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Sipuleucel-T immunotherapy for castration-resistant prostate cancer | Q27860648 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| STATs in cancer inflammation and immunity: a leading role for STAT3 | Q29547203 | ||
| Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Q29547224 | ||
| Immunobiology of dendritic cells | Q29547465 | ||
| Cancer immunotherapy via dendritic cells | Q29615444 | ||
| Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity | Q40232187 | ||
| Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate | Q40368427 | ||
| Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment | Q40400501 | ||
| Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients | Q40570530 | ||
| CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. | Q40614121 | ||
| Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells | Q40623531 | ||
| Tumor antigens recognized by T cells | Q41504896 | ||
| Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens | Q41668632 | ||
| Dendritic cell-targeted vaccines--hope or hype? | Q42696952 | ||
| Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells | Q43083716 | ||
| Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study | Q43166491 | ||
| Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients | Q43893055 | ||
| Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma | Q44980797 | ||
| Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients | Q46180952 | ||
| Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report | Q46352800 | ||
| Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial | Q46522696 | ||
| Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells | Q46578425 | ||
| Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration | Q46720423 | ||
| The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity | Q46764367 | ||
| Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients | Q48030305 | ||
| CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo | Q48266405 | ||
| A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma | Q49112423 | ||
| Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. | Q55066427 | ||
| T-cell apoptosis in human glioblastoma multiforme: implications for immunotherapy. | Q55470208 | ||
| Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. | Q55471753 | ||
| Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells | Q55473959 | ||
| Dendritic Cells Pulsed with a Tumor-specific Peptide Induce Long-lasting Immunity and Are Effective against Murine Intracerebral Melanoma | Q60922528 | ||
| Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth | Q72057620 | ||
| Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells | Q74310288 | ||
| Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine | Q74424662 | ||
| Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? | Q74675085 | ||
| Combination of ?-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: Approach to treatment of advanced stage cancer | Q77357816 | ||
| Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease | Q78108906 | ||
| Tolerogenic dendritic cells | Q29618755 | ||
| Immunosuppressive networks in the tumour environment and their therapeutic relevance | Q29619244 | ||
| Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates | Q29620051 | ||
| Immunosuppressive strategies that are mediated by tumor cells | Q29636247 | ||
| Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application | Q33536357 | ||
| Dendritic cell vaccines for cancer immunotherapy | Q33540299 | ||
| Immune defects observed in patients with primary malignant brain tumors | Q33850749 | ||
| Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial | Q34242939 | ||
| Active immunization against cancer with dendritic cells: The near future | Q34464304 | ||
| Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. | Q34649397 | ||
| Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo | Q34666875 | ||
| Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy | Q34764143 | ||
| Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma. | Q35763478 | ||
| Manipulating dendritic cell biology for the active immunotherapy of cancer | Q35825249 | ||
| Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics | Q36200438 | ||
| Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells | Q36369028 | ||
| Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. | Q36370290 | ||
| Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma | Q36375683 | ||
| Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance | Q36376611 | ||
| Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors | Q36380683 | ||
| Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma | Q36523499 | ||
| Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients | Q36597942 | ||
| Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial | Q36671200 | ||
| Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study | Q36695932 | ||
| Immunological decision-making: how does the immune system decide to mount a helper T-cell response? | Q36993451 | ||
| Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy | Q37116373 | ||
| Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. | Q37154132 | ||
| Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters | Q37249394 | ||
| Cancer immunotherapy by dendritic cells | Q37272237 | ||
| Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection | Q37397827 | ||
| Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells | Q37600964 | ||
| Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors | Q37735454 | ||
| Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets. | Q38208309 | ||
| Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors | Q38641806 | ||
| Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. | Q40143655 | ||
| P433 | issue | 2 | |
| P921 | main subject | dendritic cell | Q506253 |
| P304 | page(s) | 223-235 | |
| P577 | publication date | 2017-04-22 | |
| P1433 | published in | Journal of Neuro-Oncology | Q15752119 |
| P1476 | title | Dendritic cell based vaccination strategy: an evolving paradigm | |
| P478 | volume | 133 |
| Q61165112 | B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses |
| Q58606449 | CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors |
| Q49260236 | Cancer vaccine: learning lessons from immune checkpoint inhibitors |
| Q38635512 | Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma |
| Q53819014 | Heat shock protein peptide complex-96 vaccination for newly diagnosed glioblastoma: a phase I, single-arm trial |
| Q89286968 | Immune consequences induced by photodynamic therapy in non-melanoma skin cancers: a review |
| Q55150815 | Leukocyte-derived biomimetic nanoparticulate drug delivery systems for cancer therapy. |
| Q92827446 | Neoantigen vaccine: an emerging tumor immunotherapy |
| Q90643353 | Primary brain tumours in adults |
| Q92092437 | The role of the immune system in brain metastasis |
Search more.